Dual Inhibition of HDAC and Tyrosine Kinase Signaling Pathways with CUDC-907 Inhibits Thyroid Cancer Growth and Metastases

PURPOSE: There is currently no standard therapy for anaplastic thyroid cancer (ATC) and poorly differentiated thyroid cancer (PDTC), which account for two-thirds of thyroid cancer-related deaths. Driver mutations in the PI3K/AKT and RAF/RAS/MEK/ERK pathways are common in ATC and PDTC. Histone deacet...

Full description

Saved in:

Bibliographic Details
Published in:	Clin Cancer Res
Main Authors:	Kotian, Shweta, Zhang, Lisa, Boufraqech, Myriem, Gaskins, Kelli, Gara, Sudheer Kumar, Quezado, Martha, Nilubol, Naris, Kebebew, Electron
Format:	Artigo
Language:	Inglês
Published:	2017
Subjects:	Article
Online Access:	https://ncbi.nlm.nih.gov/pmc/articles/PMC6959516/ https://ncbi.nlm.nih.gov/pubmed/28600475 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-17-1043
Tags:	Add Tag No Tags, Be the first to tag this record!

Dual Inhibition of HDAC and Tyrosine Kinase Signaling Pathways with CUDC-907 Inhibits Thyroid Cancer Growth and Metastases

Similar Items